These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 37934376

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V, Margolis D, Schackman BR, Jalali A.
    JAMA Netw Open; 2023 Nov 01; 6(11):e2344856. PubMed ID: 38019516
    [Abstract] [Full Text] [Related]

  • 7. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R.
    Eur Urol; 2021 Mar 01; 79(3):413-418. PubMed ID: 33341285
    [Abstract] [Full Text] [Related]

  • 8. Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer .
    Voter AF, Werner RA, Pienta KJ, Gorin MA, Pomper MG, Solnes LB, Rowe SP.
    Expert Rev Anticancer Ther; 2022 Jul 01; 22(7):681-694. PubMed ID: 35603510
    [Abstract] [Full Text] [Related]

  • 9. Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer.
    Gordon LG, Elliott TM, Joshi A, Williams ED, Vela I.
    Clin Exp Metastasis; 2020 Apr 01; 37(2):305-312. PubMed ID: 32064552
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD, Smith NJ, Feng C, Jeyakumar S, Castaigne JG, Faghmous I, Masouleh BK, Malone DC, Bishop MR.
    Adv Ther; 2022 Aug 01; 39(8):3678-3695. PubMed ID: 35727476
    [Abstract] [Full Text] [Related]

  • 11. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18 F PET/CT in prostate cancer patients in early biochemical failure.
    Maliha PG, Nolet B, Ebrahim A, Abikhzer G, Chaussé G, Bahoric B, Niazi T, Probst S.
    Nucl Med Commun; 2023 Mar 01; 44(3):187-193. PubMed ID: 36525002
    [Abstract] [Full Text] [Related]

  • 12. Utility of 18F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study.
    Galgano SJ, McDonald AM, Rais-Bahrami S, Porter KK, Choudhary G, Burgan C, Bhambhvani P, Nix JW, Morgan DE, Li Y, Thomas JV, McConathy J.
    AJR Am J Roentgenol; 2021 Sep 01; 217(3):720-729. PubMed ID: 33052718
    [Abstract] [Full Text] [Related]

  • 13. Effect of hormonal therapy on 18F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen.
    Bulbul JE, Hashem A, Grybowski D, Joyce C, Rashad E, Gabriel MS, Wagner RH, Savir-Baruch B.
    Urol Oncol; 2022 Aug 01; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.
    Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.
    J Nucl Med; 2018 May 01; 59(5):789-794. PubMed ID: 29242404
    [Abstract] [Full Text] [Related]

  • 15. PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
    Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS.
    Radiology; 2020 Jul 01; 296(1):44-55. PubMed ID: 32396045
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, Tollens F, Ricke J, Rübenthaler J, Schmidt-Hegemann NS, Herlemann A, Unterrainer M, Kunz WG.
    J Natl Compr Canc Netw; 2023 Jan 01; 21(1):43-50.e2. PubMed ID: 36634610
    [Abstract] [Full Text] [Related]

  • 20. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.